Immunity and protection by adoptive transfer of dendritic cells transfected with hepatitis C NS3/4A mRNA

Vaccine

Volumn 25, Issue 10, 2007, Pages 1701-1711

  Yu, Hong ^a   Babiuk, Lorne A ^a   van Drunen Littel van den Hurk, Sylvia ^a  

^a UNIVERSITY OF SASKATCHEWAN   (Canada)

Author keywords

Cytotoxicity; Dendritic cells; Hepatitis C; NS3 4A; Vaccination

Indexed keywords

ENHANCED GREEN FLUORESCENT PROTEIN; MESSENGER RNA; VIRUS VACCINE;

ADOLESCENT; ADOPTIVE TRANSFER; ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; CELL FUNCTION; CELL MIGRATION; CELLULAR IMMUNITY; DENDRITIC CELL; ELECTROPORATION; EX VIVO STUDY; FEMALE; GENETIC TRANSFECTION; HEPATITIS C; IMMUNE RESPONSE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; T LYMPHOCYTE ACTIVATION; VACCINATION; VACCINIA VIRUS;

ADOPTIVE TRANSFER; ANIMALS; CARRIER PROTEINS; CELLS, CULTURED; DENDRITIC CELLS; DISEASE MODELS, ANIMAL; ELECTROPORATION; GENE EXPRESSION; GENES, REPORTER; GREEN FLUORESCENT PROTEINS; HEPACIVIRUS; HEPATITIS C; LYMPHOCYTE ACTIVATION; MICE; MICE, INBRED BALB C; RNA, MESSENGER; T-LYMPHOCYTES; TRANSFECTION; VACCINATION; VACCINIA; VACCINIA VIRUS; VIRAL NONSTRUCTURAL PROTEINS; VIRAL PROTEINS; VIREMIA;

EID: 33846610640     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2006.11.046     Document Type: Article

References (55)

1. Inchauspe G., and Feinstone S. Development of a hepatitis C virus vaccine. Clin Liver Dis 7 1 (2003) 243-259 xi
2. Curry M.P. Hepatitis B and hepatitis C viruses in liver transplantation. Transplantation 78 7 (2004) 955-963
3. Fried M.W., and Hadziyannis S.J. Treatment of chronic hepatitis C infection with peginterferons plus ribavirin. Semin Liver Dis 24 Suppl. 2 (2004) 47-54
4. Manns M.P., McHutchison J.G., Gordon S.C., Rustgi V.K., Shiffman M., Reindollar R., et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 358 9286 (2001) 958-965
5. Nair S., and Boczkowski D. RNA-transfected dendritic cells. Expert Rev Vaccines 1 4 (2002) 507-513
6. Banchereau J., Schuler-Thurner B., Palucka A.K., and Schuler G. Dendritic cells as vectors for therapy. Cell 106 3 (2001) 271-274
7. Cerundolo V., Hermans I.F., and Salio M. Dendritic cells: a journey from laboratory to clinic. Nat Immunol 5 1 (2004) 7-10
8. Pouniotis D.S., Proudfoot O., Bogdanoska V., Apostolopoulos V., Fifis T., and Plebanski M. Dendritic cells induce immunity and long-lasting protection against blood-stage malaria despite an in vitro parasite-induced maturation defect. Infect Immun 72 9 (2004) 5331-5339
9. Brown K., Gao W., Alber S., Trichel A., Murphey-Corb M., Watkins S.C., et al. Adenovirus-transduced dendritic cells injected into skin or lymph node prime potent simian immunodeficiency virus-specific T cell immunity in monkeys. J Immunol 171 12 (2003) 6875-6882
10. d'Ostiani C.F., Del Sero G., Bacci A., Montagnoli C., Spreca A., Mencacci A., et al. Dendritic cells discriminate between yeasts and hyphae of the fungus Candida albicans. Implications for initiation of T helper cell immunity in vitro and in vivo. J Exp Med 191 10 (2000) 1661-1674
11. Berberich C., Ramirez-Pineda J.R., Hambrecht C., Alber G., Skeiky Y.A., and Moll H. Dendritic cell (DC)-based protection against an intracellular pathogen is dependent upon DC-derived IL-12 and can be induced by molecularly defined antigens. J Immunol 170 6 (2003) 3171-3179
12. Ramirez-Pineda J.R., Frohlich A., Berberich C., and Moll H. Dendritic cells (DC) activated by CpG DNA ex vivo are potent inducers of host resistance to an intracellular pathogen that is independent of IL-12 derived from the immunizing DC. J Immunol 172 10 (2004) 6281-6289
13. + T cells from patients with cervical cancer are cross-reactive with the coronavirus NS2 protein. J Virol 77 9 (2003) 5464-5474
14. Ludewig B., Ehl S., Karrer U., Odermatt B., Hengartner H., and Zinkernagel R.M. Dendritic cells efficiently induce protective antiviral immunity. J Virol 72 5 (1998) 3812-3818
15. Ludewig B., McCoy K., Pericin M., Ochsenbein A.F., Dumrese T., Odermatt B., et al. Rapid peptide turnover and inefficient presentation of exogenous antigen critically limit the activation of self-reactive CTL by dendritic cells. J Immunol 166 6 (2001) 3678-3687
16. Schuler-Thurner B., Schultz E.S., Berger T.G., Weinlich G., Ebner S., Woerl P., et al. Rapid induction of tumor-specific type 1 T helper cells in metastatic melanoma patients by vaccination with mature, cryopreserved, peptide-loaded monocyte-derived dendritic cells. J Exp Med 195 10 (2002) 1279-1288
17. Yu J.S., Wheeler C.J., Zeltzer P.M., Ying H., Finger D.N., Lee P.K., et al. Vaccination of malignant glioma patients with peptide-pulsed dendritic cells elicits systemic cytotoxicity and intracranial T-cell infiltration. Cancer Res 61 3 (2001) 842-847
18. Nonn M., Schinz M., Zumbach K., Pawlita M., Schneider A., Durst M., et al. Dendritic cell-based tumor vaccine for cervical cancer I: in vitro stimulation with recombinant protein-pulsed dendritic cells induces specific T cells to HPV16 E7 or HPV18 E7. J Cancer Res Clin Oncol 129 9 (2003) 511-520
19. Strobel I., Berchtold S., Gotze A., Schulze U., Schuler G., and Steinkasserer A. Human dendritic cells transfected with either RNA or DNA encoding influenza matrix protein M1 differ in their ability to stimulate cytotoxic T lymphocytes. Gene Ther 7 23 (2000) 2028-2035
20. Milazzo C., Reichardt V.L., Muller M.R., Grunebach F., and Brossart P. Induction of myeloma-specific cytotoxic T cells using dendritic cells transfected with tumor-derived RNA. Blood 101 3 (2003) 977-982
21. Worgall S., Busch A., Rivara M., Bonnyay D., Leopold P.L., Merritt R., et al. Modification to the capsid of the adenovirus vector that enhances dendritic cell infection and transgene-specific cellular immune responses. J Virol 78 5 (2004) 2572-2580
22. Gilboa E., and Vieweg J. Cancer immunotherapy with mRNA-transfected dendritic cells. Immunol Rev 199 (2004) 251-263
23. Ponsaerts P., Van Tendeloo V.F., and Berneman Z.N. Cancer immunotherapy using RNA-loaded dendritic cells. Clin Exp Immunol 134 3 (2003) 378-384
24. + T-cell epitope within nonstructural protein 3 in acute hepatitis C virus infection. J Virol 71 8 (1997) 6011-6019
25. Jiao X., Wang R.Y., Feng Z., Alter H.J., and Shih J.W. Modulation of cellular immune response against hepatitis C virus nonstructural protein 3 by cationic liposome encapsulated DNA immunization. Hepatology 37 2 (2003) 452-460
26. + T-cell determinants within the NS3 protein in subjects with spontaneously resolved HCV infection. Hepatology 37 3 (2003) 577-589
27. Wolk B., Sansonno D., Krausslich H.G., Dammacco F., Rice C.M., Blum H.E., et al. Subcellular localization, stability, and trans-cleavage competence of the hepatitis C virus NS3-NS4A complex expressed in tetracycline-regulated cell lines. J Virol 74 5 (2000) 2293-2304
28. Tanji Y., Hijikata M., Satoh S., Kaneko T., and Shimotohno K. Hepatitis C virus-encoded nonstructural protein NS4A has versatile functions in viral protein processing. J Virol 69 3 (1995) 1575-1581
29. Frelin L., Alheim M., Chen A., Soderholm J., Rozell B., Barnfield C., et al. Low dose and gene gun immunization with a hepatitis C virus nonstructural (NS) 3 DNA-based vaccine containing NS4A inhibit NS3/4A-expressing tumors in vivo. Gene Ther 10 8 (2003) 686-699
30. Lutz M.B., Kukutsch N., Ogilvie A.L., Rossner S., Koch F., Romani N., et al. An advanced culture method for generating large quantities of highly pure dendritic cells from mouse bone marrow. J Immunol Methods 223 1 (1999) 77-92
31. Van Meirvenne S., Straetman L., Heirman C., Dullaers M., De Greef C., Van Tendeloo V., et al. Efficient genetic modification of murine dendritic cells by electroporation with mRNA. Cancer Gene Ther 9 9 (2002) 787-797
32. Liao X., Li Y., Bonini C., Nair S., Gilboa E., Greenberg P.D., et al. Transfection of RNA encoding tumor antigens following maturation of dendritic cells leads to prolonged presentation of antigen and the generation of high-affinity tumor-reactive cytotoxic T lymphocytes. Mol Ther 9 5 (2004) 757-764
33. Bryan L.A., Griebel P.J., Haines D.M., Davis W.C., and Allen J.R. Immunocytochemical identification of bovine Langerhans cells by use of a monoclonal antibody directed against class II MHC antigens. J Histochem Cytochem 36 8 (1988) 991-995
34. Yu H., Huang H., Xiang J., Babiuk L.A., and van Drunen Littel-van den Hurk S. Dendritic cells pulsed with hepatitis C virus NS3 protein induce immune responses and protection from infection with recombinant vaccinia virus expressing NS3. J Gen Virol 87 Pt 1 (2006) 1-10
35. Baca-Estrada M.E., Snider M., Tikoo S.K., Harland R., Babiuk L.A., and van Drunen Littel-van den Hurk S. Immunogenicity of bovine herpesvirus 1 glycoprotein D in mice: effect of antigen form on the induction of cellular and humoral immune responses. Viral Immunol 9 1 (1996) 11-22
36. Yu H., Babiuk L.A., and van Drunen Littel-van den Hurk S. Priming with CpG-enriched plasmid and boosting with protein formulated with CpG oligodeoxynucleotides and Quil A induces strong cellular and humoral immune responses to hepatitis C virus NS3. J Gen Virol 85 Pt 6 (2004) 1533-1543
37. Ioannou X.P., Griebel P., Hecker R., Babiuk L.A., and van Drunen Littel-van den Hurk S. The immunogenicity and protective efficacy of bovine herpesvirus 1 glycoprotein D plus Emulsigen are increased by formulation with CpG oligodeoxynucleotides. J Virol 76 18 (2002) 9002-9010
38. Lewis P.J., van Drunen Littel-van den H., and Babiuk L.A. Altering the cellular location of an antigen expressed by a DNA-based vaccine modulates the immune response. J Virol 73 12 (1999) 10214-10223
39. Murata K., Lechmann M., Qiao M., Gunji T., Alter H.J., and Liang T.J. Immunization with hepatitis C virus-like particles protects mice from recombinant hepatitis C virus-vaccinia infection. Proc Natl Acad Sci USA 100 11 (2003) 6753-6758
40. Pancholi P., Perkus M., Tricoche N., Liu Q., and Prince A.M. DNA immunization with hepatitis C virus (HCV) polycistronic genes or immunization by HCV DNA priming-recombinant canarypox virus boosting induces immune responses and protection from recombinant HCV-vaccinia virus infection in HLA-A2.1-transgenic mice. J Virol 77 1 (2003) 382-390
41. van den Broeke L.T., Daschbach E., Thomas E.K., Andringa G., and Berzofsky J.A. Dendritic cell-induced activation of adaptive and innate antitumor immunity. J Immunol 171 11 (2003) 5842-5852
42. Grunebach F., Muller M.R., and Brossart P. New developments in dendritic cell-based vaccinations: RNA translated into clinics. Cancer Immunol Immunother 54 6 (2005) 517-525
43. Muller M.R., Grunebach F., Nencioni A., and Brossart P. Transfection of dendritic cells with RNA induces CD4- and CD8-mediated T cell immunity against breast carcinomas and reveals the immunodominance of presented T cell epitopes. J Immunol 170 12 (2003) 5892-5896
44. + T cell responses in patients with metastatic prostate cancer. J Immunol 174 6 (2005) 3798-3807
45. + T cells and antiviral immunity. Immunity 20 1 (2004) 47-58
46. Matsui M., Moriya O., Abdel-Aziz N., Matsuura Y., Miyamura T., and Akatsuka T. Induction of hepatitis C virus-specific cytotoxic T lymphocytes in mice by immunization with dendritic cells transduced with replication-defective recombinant adenovirus. Vaccine 21 3-4 (2002) 211-220
47. Encke J., Findeklee J., Geib J., Pfaff E., and Stremmel W. Prophylactic and therapeutic vaccination with dendritic cells against hepatitis C virus infection. Clin Exp Immunol 142 2 (2005) 362-369
48. Auffermann-Gretzinger S., Keeffe E.B., and Levy S. Impaired dendritic cell maturation in patients with chronic, but not resolved, hepatitis C virus infection. Blood 97 10 (2001) 3171-3176
49. Sarobe P., Lasarte J.J., Zabaleta A., Arribillaga L., Arina A., Melero I., et al. Hepatitis C virus structural proteins impair dendritic cell maturation and inhibit in vivo induction of cellular immune responses. J Virol 77 20 (2003) 10862-10871
50. Sarobe P., Lasarte J.J., Casares N., Lopez-Diaz de Cerio A., Baixeras E., Labarga P., et al. Abnormal priming of CD4(+) T cells by dendritic cells expressing hepatitis C virus core and E1 proteins. J Virol 76 10 (2002) 5062-5070
51. Chen M., Sallberg M., Sonnerborg A., Weiland O., Mattsson L., Jin L., et al. Limited humoral immunity in hepatitis C virus infection. Gastroenterology 116 1 (1999) 135-143
52. Rehermann B., and Chisari F.V. Cell mediated immune response to the hepatitis C virus. Curr Top Microbiol Immunol 242 (2000) 299-325
53. Lasarte J.J., Garcia-Granero M., Lopez A., Casares N., Garcia N., Civeira M.P., et al. Cellular immunity to hepatitis C virus core protein and the response to interferon in patients with chronic hepatitis C. Hepatology 28 3 (1998) 815-822
54. Gowans E.J., Jones K.L., Bharadwaj M., and Jackson D.C. Prospects for dendritic cell vaccination in persistent infection with hepatitis C virus. J Clin Virol 30 4 (2004) 283-290
55. Larsson M. The dendritic cell: the immune system's adjuvant-a strategy to develop a HCV vaccine?. Gastroenterology 130 2 (2006) 603-606